Skip to main content
Top
Published in: PharmacoEconomics 4/2014

01-04-2014 | Leading Article

Methods for Identifying the Cost-effective Case Definition Cut-Off for Sequential Monitoring Tests: An Extension of Phelps and Mushlin

Authors: Roberta Longo, Paul Baxter, Peter Hall, Jenny Hewison, Mehran Afshar, Geoff Hall, Christopher McCabe

Published in: PharmacoEconomics | Issue 4/2014

Login to get access

Abstract

The arrival of personalized medicine in the clinic means that treatment decisions will increasingly rely on test results. The challenge of limited healthcare resources means that the dissemination of these technologies will be dependent on their value in relation to their cost, i.e., their cost effectiveness. Phelps and Mushlin have described how to optimize tests to meet a cost-effectiveness target. However, when tests are applied repeatedly the case mix of the patients tested changes with each administration, and this impacts upon the value of each subsequent test administration. In this article, we present a modification of Phelps and Mushlin’s framework for diagnostic tests; to identify the cost-effective cut-off for monitoring tests. Using the Ca125 test monitoring for relapse in ovarian cancer, we show how the repeated use of the initial cut-off can lead to a substantially increased false-negative rate compared with the monitoring cut-off—over 4 % higher than in this example—with the associated harms for individual and population health.
Literature
3.
go back to reference Phelps CE, Mushlin A. Focussing technology assessment using decision theory. Med Decis Mak. 1988;8(4):279–89.CrossRef Phelps CE, Mushlin A. Focussing technology assessment using decision theory. Med Decis Mak. 1988;8(4):279–89.CrossRef
4.
5.
go back to reference Carroll PR, Whitson JM, Cooperberg MR. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes? J Clin Oncol. 2011;28(4):345–6.CrossRef Carroll PR, Whitson JM, Cooperberg MR. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes? J Clin Oncol. 2011;28(4):345–6.CrossRef
6.
go back to reference Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK. Swart AM; MRC OV05; EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155–63.PubMedCrossRef Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK. Swart AM; MRC OV05; EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155–63.PubMedCrossRef
7.
go back to reference Parkes J, Guha IN, Roderick P, Harris S, Cross R, Manos MM, Irving W, Zaitoun A, Wheatley M, Ryder S, Rosenberg W. Enhanced liver fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat. 2011;18(1):23–31. doi:10.1111/j.1365-2893.2009.01263.x.PubMedCrossRef Parkes J, Guha IN, Roderick P, Harris S, Cross R, Manos MM, Irving W, Zaitoun A, Wheatley M, Ryder S, Rosenberg W. Enhanced liver fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat. 2011;18(1):23–31. doi:10.​1111/​j.​1365-2893.​2009.​01263.​x.PubMedCrossRef
8.
go back to reference Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: Wiley; 2000. p. 156–164. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: Wiley; 2000. p. 156–164.
9.
go back to reference McCabe C, Claxton K, Culyer AJ. The NICE cost effectiveness threshold: what it is and what that means? PharmacoEconomics. 2008;26(9):733–44.PubMedCrossRef McCabe C, Claxton K, Culyer AJ. The NICE cost effectiveness threshold: what it is and what that means? PharmacoEconomics. 2008;26(9):733–44.PubMedCrossRef
10.
go back to reference NICE. Guide to the Methods of Technology Appraisal. London; 2008. NICE. Guide to the Methods of Technology Appraisal. London; 2008.
12.
go back to reference Grey DR, Morgan BJT. Some aspects of ROC curve-fitting: normal and logistic models. J Math Psychol. 1972;9:128–39.CrossRef Grey DR, Morgan BJT. Some aspects of ROC curve-fitting: normal and logistic models. J Math Psychol. 1972;9:128–39.CrossRef
14.
go back to reference Hanley JS. The robustness of the binormal assumptions used in fitting ROC curves. Med Decis Mak. 1988;8:197–203.CrossRef Hanley JS. The robustness of the binormal assumptions used in fitting ROC curves. Med Decis Mak. 1988;8:197–203.CrossRef
15.
go back to reference Metz CE, Herman BA, Shen J-H. Maximum-likelihood estimation of ROC curves from continuously-distributed data. Stat Med. 1998;17:1033–53.PubMedCrossRef Metz CE, Herman BA, Shen J-H. Maximum-likelihood estimation of ROC curves from continuously-distributed data. Stat Med. 1998;17:1033–53.PubMedCrossRef
16.
go back to reference Metz CE, Pan X. Proper binormal ROC curves: theory and maximum-likelihood estimation. J Math Psychol. 1999;43:1–33.PubMedCrossRef Metz CE, Pan X. Proper binormal ROC curves: theory and maximum-likelihood estimation. J Math Psychol. 1999;43:1–33.PubMedCrossRef
17.
go back to reference Burden RL, Faires JD. Numerical analysis. 7th ed. Conn: Brooks/Cole; 2000. Burden RL, Faires JD. Numerical analysis. 7th ed. Conn: Brooks/Cole; 2000.
18.
go back to reference Pesce LL, Metz CE. Reliable and computationally efficient maximum-likelihood estimation of “proper” binormal ROC curves. Acad Radiol. 2007;14:814–29.PubMedCentralPubMedCrossRef Pesce LL, Metz CE. Reliable and computationally efficient maximum-likelihood estimation of “proper” binormal ROC curves. Acad Radiol. 2007;14:814–29.PubMedCentralPubMedCrossRef
19.
go back to reference National Institute for Health and Clinical Excellence. Ovarian cancer: the recognition and initial management of ovarian cancer. London: NICE Full Guideline; 2011. National Institute for Health and Clinical Excellence. Ovarian cancer: the recognition and initial management of ovarian cancer. London: NICE Full Guideline; 2011.
20.
go back to reference Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316:736–41.PubMedCentralPubMedCrossRef Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316:736–41.PubMedCentralPubMedCrossRef
21.
go back to reference Mason H, Jones-Lee M, Donaldson C. Modelling the monetary value of a QALY: a new approach based on UK data. Health Econ. 2009;18(8):933–50.PubMedCrossRef Mason H, Jones-Lee M, Donaldson C. Modelling the monetary value of a QALY: a new approach based on UK data. Health Econ. 2009;18(8):933–50.PubMedCrossRef
22.
go back to reference Towse A. Should NICE’s threshold range for cost per QALY be raised? Yes. BMJ. 2009;338:268–9.CrossRef Towse A. Should NICE’s threshold range for cost per QALY be raised? Yes. BMJ. 2009;338:268–9.CrossRef
24.
go back to reference Novielli N, Cooper NJ, Sutton AJ. Evaluating the cost-effectiveness of diagnostic tests in combination: is it important to allow for performance dependency? Value Health. 2013;16(4):536–41.PubMedCrossRef Novielli N, Cooper NJ, Sutton AJ. Evaluating the cost-effectiveness of diagnostic tests in combination: is it important to allow for performance dependency? Value Health. 2013;16(4):536–41.PubMedCrossRef
Metadata
Title
Methods for Identifying the Cost-effective Case Definition Cut-Off for Sequential Monitoring Tests: An Extension of Phelps and Mushlin
Authors
Roberta Longo
Paul Baxter
Peter Hall
Jenny Hewison
Mehran Afshar
Geoff Hall
Christopher McCabe
Publication date
01-04-2014
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 4/2014
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-014-0134-1

Other articles of this Issue 4/2014

PharmacoEconomics 4/2014 Go to the issue